home / stock / ocgn / ocgn quote
Last: | $ |
---|---|
Change Percent: | -6.44% |
Open: | $0.6237 |
Close: | $0.568 |
High: | $0.6237 |
Low: | $0.553 |
Volume: | 2,453,528 |
Last Trade Date Time: | 02/12/2020 04:43:56 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$ | $0.6237 | $0.568 | $0.6237 | $0.553 | 2,453,528 | 02-12-2020 |
$ | $0.5807 | $0.6071 | $0.6489 | $0.565 | 5,142,878 | 02-11-2020 |
$ | $0.52 | $0.56 | $0.5695 | $0.51 | 2,511,846 | 02-10-2020 |
$ | $0.53 | $0.5107 | $0.54 | $0.505 | 1,855,873 | 02-07-2020 |
$ | $0.5404 | $0.5351 | $0.5404 | $0.5205 | 1,469,805 | 02-06-2020 |
$ | $0.5717 | $0.5439 | $0.573 | $0.5311 | 1,655,644 | 02-05-2020 |
$ | $0.525 | $0.5512 | $0.5686 | $0.5216 | 2,188,786 | 02-04-2020 |
$ | $0.5202 | $0.52 | $0.5588 | $0.51 | 1,875,004 | 02-03-2020 |
$ | $0.5154 | $0.5302 | $0.545 | $0.50 | 3,091,906 | 01-31-2020 |
$ | $0.5877 | $0.5346 | $0.59 | $0.525 | 3,803,475 | 01-30-2020 |
$ | $0.62 | $0.589978 | $0.64 | $0.582 | 2,064,788 | 01-29-2020 |
$ | $0.60 | $0.6288 | $0.64 | $0.571 | 3,416,636 | 01-28-2020 |
$ | $0.66 | $0.5924 | $0.684 | $0.58 | 4,494,943 | 01-27-2020 |
$ | $0.6983 | $0.6695 | $0.7325 | $0.66 | 6,143,892 | 01-24-2020 |
$ | $0.73 | $0.6976 | $0.735 | $0.685 | 2,944,139 | 01-23-2020 |
$ | $0.6803 | $0.707 | $0.755 | $0.65 | 6,684,029 | 01-22-2020 |
$ | $0.72 | $0.69 | $0.729 | $0.66 | 5,523,033 | 01-21-2020 |
$ | $0.73 | $0.7278 | $0.8388 | $0.71 | 21,466,353 | 01-20-2020 |
$ | $0.73 | $0.7278 | $0.8388 | $0.71 | 21,170,820 | 01-17-2020 |
$ | $0.66 | $0.6965 | $0.718 | $0.6291 | 8,789,054 | 01-16-2020 |
News, Short Squeeze, Breakout and More Instantly...
Ocugen, Inc. Company Name:
OCGN Stock Symbol:
NYSE Market:
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
MALVERN, Pa., April 19, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that dosing is complete...
LOS ANGELES, April 16, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class...